Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
Homes and commercial buildings win Oak Park preservation awards. Pieritz Bros. renovation one of two commercial winners ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results